Sickle cell disease: a review

Area of Science:

• Hematology
• Genetics
• Immunology

Background:

• Sickle cell disease (SCD) arises from a single amino acid substitution in hemoglobin, leading to abnormal red blood cell (RBC) sickling.
• Sickled RBCs cause vaso-occlusion, inflammation, and chronic hemolytic anemia, significantly impacting patient health.
• Advances in newborn screening and early interventions have reduced childhood mortality from SCD.

Purpose of the Study:

• To summarize current therapeutic strategies for sickle cell disease.
• To highlight the benefits and risks associated with blood transfusions in SCD management.
• To discuss the potential of hematopoietic stem cell transplantation as a curative option.

Main Methods:

• Review of established and emerging treatments for sickle cell disease.
• Analysis of transfusion therapy protocols, including indications and complications.
• Exploration of hematopoietic progenitor cell transplantation for severe SCD cases.

Main Results:

• Blood transfusion is a primary therapy to reduce sickle hemoglobin (Hgb S) and prevent complications like stroke and acute chest syndrome.
• Transfusion risks include infectious disease transmission, alloimmunization, and iron overload, necessitating antigen-matched, leukoreduced RBCs.
• Hematopoietic progenitor cell transplantation offers a potential cure for severe SCD unresponsive to conventional treatments.

Conclusions:

• Effective management of sickle cell disease involves a multi-faceted approach, balancing therapeutic benefits with potential risks.
• Preventing alloimmunization through careful transfusion practices is crucial for long-term patient care.
• Hematopoietic stem cell transplantation represents a curative pathway for select patients with severe sickle cell disease.